Charles Schwab
CDLX icon

Charles Schwab’s Cardlytics CDLX Stock Holding History

Charles Schwab’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-26,972
Closed -$444K – 3475
2025
Q2 		$444K Sell
26,972
-7,097
-21% -$123K ﹤0.01% 3176
2025
Q1 		$620K Sell
34,069
-6,186
-15% -$177K ﹤0.01% 3002
2024
Q4 		$1.49M Buy
40,255
+1,221
+3% +$46.7K ﹤0.01% 2771
2024
Q3 		$1.25M Buy
39,034
+1,138
+3% +$63.2K ﹤0.01% 2855
2024
Q2 		$3.11M Buy
37,896
+6,184
+20% +$669K ﹤0.01% 2549
2024
Q1 		$4.6M Buy
31,712
+277
+0.9% +$23.4K ﹤0.01% 2320
2023
Q4 		$2.9M Buy
31,435
+3,126
+11% +$318K ﹤0.01% 2511
2023
Q3 		$4.67M Buy
28,309
+3,223
+13% +$419K ﹤0.01% 2292
2023
Q2 		$1.59M Buy
25,086
+680
+3% +$41.2K ﹤0.01% 2625
2023
Q1 		$829K Buy
24,406
+3,456
+16% +$181K ﹤0.01% 2802
2022
Q4 		$1.21M Sell
20,950
-2,772
-12% -$171K ﹤0.01% 2719
2022
Q3 		$2.23M Sell
23,722
-310
-1% -$44.1K ﹤0.01% 2554
2022
Q2 		$5.36M Buy
24,032
+83
+0.3% +$27.8K ﹤0.01% 2160
2022
Q1 		$13.2M Buy
23,949
+629
+3% +$380K ﹤0.01% 1799
2021
Q4 		$15.4M Buy
23,320
+570
+3% +$436K ﹤0.01% 1762
2021
Q3 		$19.1M Buy
22,750
+225
+1% +$228K 0.01% 1630
2021
Q2 		$28.6M Buy
22,525
+1,507
+7% +$1.7M 0.01% 1288
2021
Q1 		$23.1M Buy
21,018
+3,138
+18% +$4.14M 0.01% 1408
2020
Q4 		$25.5M Buy
17,880
+296
+2% +$316K 0.01% 1219
2020
Q3 		$12.4M Buy
17,584
+2,657
+18% +$1.93M 0.01% 1537
2020
Q2 		$10.4M Buy
14,927
+3,704
+33% +$2.14M 0.01% 1622
2020
Q1 		$3.92M Buy
11,223
+218
+2% +$154K ﹤0.01% 1946
2019
Q4 		$6.92M Buy
11,005
+1,056
+11% +$516K ﹤0.01% 1853
2019
Q3 		$3.33M Buy
9,949
+6,528
+191% +$2.09M ﹤0.01% 2175
2019
Q2 		$889K Buy
3,421
+2,034
+147% +$407K ﹤0.01% 2616
2019
Q1 		$230K Hold
1,387
– – ﹤0.01% 2997
2018
Q4 		$151K Hold
1,387
– – ﹤0.01% 3051
2018
Q3 		$348K Buy
1,387
+407
+42% +$87.6K ﹤0.01% 2960
2018
Q2 		$214K Buy
+980
New +$181K ﹤0.01% 3055

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Charles Schwab's CDLX Position: Q3 2025 in Review

Charles Schwab sold out of Cardlytics (CDLX) in Q3 2025, closing a stake of 26,972 shares — an estimated $444K sold.

Charles Schwab first reported a position in CDLX in Q2 2018 and held it in 29 quarters. The position peaked at $28.6M in Q2 2021. 81 funds tracked by Wall St. Rank hold CDLX as of Q3 2025.

  • Charles Schwab reported no remaining Cardlytics position as of Q3 2025 after selling out during the quarter.
  • Charles Schwab sold 26,972 Cardlytics shares in Q3 2025, an estimated $444K.
  • Charles Schwab first reported a position in Cardlytics in Q2 2018 and held it in 29 quarters.
  • Charles Schwab's Cardlytics position peaked at $28.6M in Q2 2021.
  • 81 funds tracked by Wall St. Rank held Cardlytics as of Q3 2025.

Based on Charles Schwab's 13F filing for Q3 2025, filed 10 Nov 2025.